Plasma cfDNA Fragmentomics for Early pNET Detection and Differential Diagnosis of Solid Pancreatic Tumors

Prior treatment

• Receiving anti-tumor treatment before surgery, including chemotherapy, embolization, ablation, radiotherapy, and molecular targeted therapy;
• Ongoing fever or recipient of anti-inflammation therapy within 14 days prior to study blood draw;
• Recipient of blood transfusion within 30 days prior to study blood draw;
• Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant;

Other illness

• Currently diagnosed with other types of tumors or any cancer history;
• Diagnosed with familial syndromes;
• Poor health condition and not suitable for blood draw;
• Any other disease/condition deemed not suitable for study enrollment by researcher.

Other

• Pathological diagnosis was not pancreatic neuroendocrine tumor, pancreatic ductal adenocarcinoma or solid pseudopapillary tumor;

• Age 18 and above, regardless of gender;
• Histopathological diagnosis with non-functional pancreatic neuroendocrine tumor, pancreatic ductal adenocarcinoma or solid pseudopapillary tumor;
• Not receiving any anti-tumor treatment before surgery, including chemotherapy, embolization, ablation, radiotherapy, and molecular targeted therapy;
• No obvious surgical contraindications;
• Able to comply with research plans, follow-up plans, and other protocol requirements;
• Voluntary participation and signed informed consent.